Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 6, 2009, Pages 1173-1179

  Ch'ang, Hui Ju ^a,b   Huang, Chin Lun ^c   Wang, Hsiu Po ^c   Shiah, Her Shyong ^a,b   Chang, Ming Chu ^c   Jan, Chang Ming ^d   Chen, Jen Shi ^e   Tien, Yu Wen ^c   Hwang, Tsann Long ^e   Lin, Jaw Town ^c   Cheng, Ann Lii ^c   Whang Peng, Jacqueline ^a   Chen, Li Tzong ^a,b,d  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Fluorouracil; Gemcitabine; Oxaliplatin; Pancreatic cancer; Phase II

Indexed keywords

ALANINE AMINOTRANSFERASE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIP; OXALIPLATIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG SAFETY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERAMMONEMIC ENCEPHALOPATHY; LUNG EMBOLISM; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CARCINOMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR GROWTH; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 69049099928     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-0980-2     Document Type: Article

References (30)

1. KR Palmer M Kerr G Knowles, et al. 1994 Chemotherapy prolongs survival in inoperable pancreatic carcinoma Br J Surg 81 6 882 885
2. B Glimelius K Hoffman PO Sjoden, et al. 1996 Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer Ann Oncol 7 6 593 600
3. HA Burris MJ Moore J Andersen, et al. 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 6 2403 2413
4. V Heinemann A Hinke S Bock, et al. 2007 Gemcitabine-based combinations (gem + x) vs Gemcitabine (gem) alone in the treatment of advanced pancreatic cancer: meta-analysis of sixteen randomized trials J Clin Oncol 25 18S 4515
5. HS Shiah AL Cheng C Hsu, et al. 2006 Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer J Gastroenterol Hepatol 21 3 531 536
6. JD Berlin S Adak DJ Vaughn, et al. 2000 A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296) Oncology 58 3 215 218
7. H Oettle M Arning U Pelzer, et al. 2000 A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer Ann Oncol 11 10 1267 1272
8. T Andre M Noirclerc P Hammel, et al. 2004 Phase II study of leucovorin, 5-fluorouracil and gemcitabine for locally advanced and metastatic pancreatic cancer (FOLFUGEM 2) Gastroenterol Clin Biol 28 8-9 645 650
9. E Raymond C Buquet-Fagot S Djelloul, et al. 1997 Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers Anticancer Drugs 8 9 876 885
10. S Faivre E Raymond JM Woynarowski, et al. 1999 Supraadditive effect of 2′, 2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines Cancer Chemother Pharmacol 44 117 123
11. C Louvet R Labianca P Hammel, et al. 2005 Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial J Clin Oncol 23 15 3509 3516
12. A Demols M Peeters M Polus, et al. 2006 Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study Br J Cancer 94 4 481 485
13. M Ghosn F Farhat J Kattan, et al. 2007 FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer Am J Clin Oncol 30 1 15 20
14. V Gebbia E Maiello F Giuliani, et al. 2007 Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice Ann Oncol 18 6S vi124 127
15. H Oettle U Pelezer J Stieler 2005 Oxaliplatin/folinic acid/5-fluorouracil [24 h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003) J Clin Oncol 23 16S 4031
16. HJ Ch'ang CC Wang AL Cheng, et al. 2006 Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer J Gastroenterol Hepatol 21 5 874 879
17. A Trotti R Byhardt J Stetz, et al. 2000 Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy Int J Radiat Oncol Biol Phys 47 1 13 47
18. AB Miller B Hoogstraten M Staquet, et al. 1981 Reporting results of cancer treatment Cancer 47 1 207 214
19. EL Kaplan P Meier 1958 Nonparametric estimation from incomplete observation J Am Stat Assoc 53 457 481
20. H Riess A Helm M Niedergethmann, et al. 2005 A randomized, prospective, multicenter, phase II trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer J Clin Oncol 23 16S 4009
21. E Poplin DE Levy J Berlin, et al. 2006 Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201) J Clin Oncol 24 18S 4004
22. M Ducreux E Mitry M Ould-Kaci, et al. 2004 Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients Ann Oncol 15 3 467 473
23. U Pelzer K Kubica J Stieler, et al. 2008 A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO003 study J Clin Oncol 26 15S 4508
24. C Garnier C Rebischung E Chirpaz, et al. 2001 Phase II study of a combination with leucovorin (LV), 5 FU bolus and infusion (FU), gemcitabine (GEM) and oxaliplatin (LOHP) (FOLFU GEMOX regimen) in locally advanced (LA) and metastatic (M) pancreatic carcinoma (APC) Proc Am Soc Clin Oncol 20 620
25. T Conroy B Paillot E Francois, et al. 2005 Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer-a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study J Clin Oncol 23 6 1228 1236
26. M Ychou F Desserigne R Guimbaud, et al. 2007 Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial J Clin Oncol 25 18S 4516
27. C Verslype E Van Cutsem M Dicato, et al. 2006 The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006 Ann Oncol 18 7S vii1 10
28. F Huguet T Andre P Hammel, et al. 2007 Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies J Clin Oncol 25 3 326 331
29. V Rana S Krishnan JL Abbruzzese, et al. 2006 Neoadjuvant chemotherapy improves outcomes of chemoradiation therapy for locally advanced pancreatic cancer J Clin Oncol 24 18S 4036
30. Chen LT, Ch'ang HJ, Huang CL et al (2008) Safety-profile of gemcitabine-based chemoradiotherapy (CRT) after triplet induction chemotherapy (CT) in locally advanced pancreatic cancer (LAPC): preliminary data from Taiwan Cooperative Oncology Group (TCOG) T1204 study. In: ASCO Gastrointestinal Cancers Symposium, Orlando; abstract 156